Overview

• The test detects chromosomal instability signatures in tumor DNA to forecast resistance to platinum-based, anthracycline and taxane chemotherapies.
• Validation used genomic and clinical data from 840 patients with breast, prostate, ovarian and sarcoma cancers.
• The assay integrates seamlessly into existing sequencing workflows by using routine tumor DNA samples.
• Researchers will conduct prospective hospital-based studies to assess clinical utility before applying for regulatory approval.
• The technology has been licensed to Cambridge startup Tailor Bio to support the personalized oncology model envisioned by the Cambridge Cancer Research Hospital.